Skip to main content

Table 4 Impact of the dual therapy on analytical parameters

From: Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

  Baseline 24 weeks P value
CD4 lymphocytes (cells/uL) 630 667 0.071*
CD4/CD8 Ratio 0.749 0.788 0.004
Creatinine (mg/dL) 0.944 0.977 0.001
Glucose (mg/dL) 95.2 96.5 0.057
Total Cholesterol/HDL 4,13 4,10 0.107
Total Cholesterol (mg/dL) 183 196 < 0.001*
HDL-cholesterol (mg/dL) 48 52 0.005
LDL-cholesterol (mg/dL) 107 124 0.003*
Triglycerides (mg/dL) 144 157 0.172
Bilirubin (mg/dL) 0.77 0.64 0.827
GOT (U/L) 40.9 30.8 0.031
GPT (U/L) 45.9 30.3 0.011
GGT (U/L) 57.5 59.4 0.040
Alkaline Phosphatase (U/L) 98 93 0.026
Hemoglobin (g/dL) 15 14.8 0.009
Platelets (×10^3/μL) 190 189 0.346
  1. *paired samples t-test (otherwise with Wilcoxon signed-rank test)